Tue, May 6, 11:41 AM (13 days ago)
**OnKure Therapeutics, Inc. (OKUR) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $0 (no revenue generated as the company is in the clinical stage). - **Profit Margins:** Negative, with a net loss of $15.9 million for Q1 2025. - **Cash Flow:** Negative, with a net decrease in cash and cash equivalents of $14.1 million. - **Earnings Changes:** Net loss increased by $6.389 million compared to Q1 2024. **Quarterly Performance Discussion:** - **Operating Expenses:** Totaled $17 million, with R&D expenses at $13.012 million and G&A expenses at $3.988 million. - **Other Income:** Interest income was $1.075 million. - **Cash Flows:** Negative cash flow from operations at $14.005 million, with minimal investing and financing activities. **Trends & Uncertainties:** - **Liquidity:** The company believes its cash resources will be sufficient to fund operations for at least the next 12 months. - **Funding Requirements:** The company will need substantial additional capital to develop product candidates and fund operations. - **Uncertainties:** Dependence on third parties for manufacturing, regulatory approval risks, and market competition. **Future Operations Impact:** - **R&D Focus:** Continued investment in clinical and preclinical programs. - **Commercialization:** Potential for OKI-219 in advanced breast cancer and other indications. - **Regulatory:** Ongoing interactions with the FDA and other regulatory authorities. **Summary:** OnKure Therapeutics, Inc. reported a net loss of $15.9 million for Q1 2025, with significant operating expenses and negative cash flow. The company is focused on developing its product candidates, particularly OKI-219, and faces uncertainties related to regulatory approval, market competition, and funding requirements. Despite these challenges, the company believes it has sufficient cash to fund operations for the next 12 months.